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ABSTRACT
Aims/Introduction: Despite there being several meta-analyses on the effects of antidi-
abetic agents in patients with gestational diabetes mellitus, the reliability of their findings
is a concern, mainly due to undetermined methodological quality of these studies. This
study aimed to assess the methodological quality of available meta-analyses and provide
a summary estimation of the effectiveness of treatments modalities.
Materials and Methods: PubMed, Web of Science and Scopus databases were com-
prehensively searched for retrieving relevant meta-analyses published in English up to
May 2020. A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) was applied to
evaluate methodological quality of eligible meta-analyses. A network meta-analysis was
used to calculate the pooled odds ratio of maternal and neonatal outcomes in gestational
diabetes mellitus patients treated with metformin or glyburide compared with those trea-
ted with insulin. The rank network analysis was carried out for ranking of the treatments
and reporting the most efficient treatment.
Results: A total of 27 and 17 studies were included for qualitative and quantitative syn-
theses, respectively; of these, just four studies were classified as high quality. The results
showed that metformin had the highest probability of being the best treatment, com-
pared with insulin and glyburide, for the majority of adverse neonatal outcomes, whereas
glyburide was the best treatment in reducing the risk of adverse maternal outcomes. The
results were not significantly changed after excluding low-quality studies.
Conclusions: This review study of available literature shows that metformin can be a
superior option in most neonatal and maternal adverse pregnancy outcomes in women
with gestational diabetes mellitus; the results need to be further updated by including
future more qualified studies.
INTRODUCTION
Gestational diabetes mellitus (GDM) is a common
endocrinopathy during pregnancy affecting 4–11% of all preg-
nancies, defined as glucose intolerance recognized at any time
in pregnancy based on defined thresholds that are less than
those considered for overt diabetes1,2. Earlier studies have
shown that GDM is associated with a higher risk of adverse
feto-maternal and neonatal complications3-6. Furthermore, there
is a general consensus that treatment should be initiated using
individual medical nutrition therapy, exercise and pharmacolog-
ical therapies if required7-9. It is well documented that appro-
priate management of GDM minimizes the risk of adverse
perinatal outcomes through controlling glycemic level10. Insulin
therapy has been accepted as a gold standard for managing
GDM, and can achieve tight maternal glucose control without
the risk of transferring across the placenta7,11,12. Oral antidia-
betic agents, mainly metformin and glyburide, are attractiveReceived 19 December 2020; revised 2 May 2021; accepted 16 May 2021
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alternatives to insulin for various reasons, including their ease
of use, low cost and unwanted side-effects, such as hypo-
glycemia and weight gain, which increases the compliance to
treatment regimens13.
However, the results of efficacy and safety of oral antidiabetic
agents are controversial; traditionally, these medications have
been avoided by women with GDM because of the potential
risks of neonatal hypoglycemia and teratogenicity associated
with placental transfer to the fetus14.
Network meta-analysis, which is also called multiple-
treatments meta-analysis, is considered as high-level evidence
for developing guidelines, in particular when there is an incon-
sistency among studies; these studies can provide the most
robust and reliable evidence on a specific topic15,16. Several
meta-analyses have been published on GDM and its related
treatments, including oral antidiabetic agents and insulin, and
the reliability of their findings is a concerning matter, mainly
due to the lack of methodological quality assessment of these
studies. In addition, most of these meta-analyses’ results are
inconclusive, mainly due to the diversity of study populations,
diagnostic thresholds for GDM, and the lack of multiple com-
parisons between oral antidiabetic agents and insulin6,11,13,17-29.
In the present study, we aimed to assess the methodological
quality of the included meta-analyses using A Measurement
Tool to Assess Systematic Reviews (AMSTAR-2) scale30. Then,
we identified the pooled odds ratio (OR) of maternal and
neonatal outcomes in GDM patients treated with oral antidia-
betic agents (metformin or glyburide), compared with those
treated with insulin, and also reported the most efficient modal-
ity in terms of reducing the risk of maternal and neonatal
adverse outcomes in women with GDM. We repeated our anal-
ysis by excluding low-quality studies assessed based on the
AMSTAR-2.
MATERIALS AND METHODS
The present systematic review and network meta-analysis were
designed according to the guidelines for the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)31
and the Cochrane Handbook for Systematic Reviews of Inter-
ventions32 to identify the pooled OR of maternal and neonatal
outcomes in GDM patients treated with oral antidiabetic agents
(metformin or glyburide), compared with those treated with
insulin, and reported the most efficient modality for managing
GDM. Furthermore, we also planned to report the most effi-
cient treatment by including only high- and moderate-quality
studies. No ethics approval was required for this systematic
review; however, the review was prospectively registered with
the National Institute for Health Research Prospero Interna-
tional Prospective Register of Systematic Reviews
(CRD42020185909).
Search strategy
PubMed (including Medline), Web of Science and Scopus data-
bases were searched for retrieving relevant meta-analyses
published in the English language from inception to May 2020.
Two authors carried out searches separately (SBG and RBY),
and any disagreements were resolved by consensus through dis-
cussing with senior authors (MA and FRT). The following key-
words, alone or in combination, were used for the search
process: (“Gestational diabetes” OR “gestational diabetes melli-
tus” OR “GDM” OR “pregnancy induced diabetes”) AND
(“oral antidiabetic agent” OR “hypoglycemic agent” OR “oral
anti-hyperglycemic agent” OR “oral antidiabetic drugs” OR
“pharmacological therapy” OR “antidiabetic medication” OR
“metformin” OR “glucophage” OR “biguanide” OR “gliben-
clamide” OR “glyburide”) AND (“review” OR “systemic review”
OR “meta-analysis”). The text words and MeSH terms were
entered depending on the databases characteristics. The refer-
ence lists from retrieved articles were also screened for addi-
tional applicable studies.
Eligibility criteria, study selection and data extraction
Studies were eligible if they fulfilled all the following conditions:
(i) they were a meta-analysis published in the English language;
(ii) study populations were women with GDM treated with
antidiabetic pharmacological therapy; (iii) studies comparing
the effects of glyburide (glibenclamide) with insulin, metformin
with insulin, or metformin with glyburide; and (iv) studies
assessing at least one of feto-maternal or neonatal outcomes.
We also excluded all studies assessing patients with pre-existing
diabetes, non-human studies, original studies, reviews, commen-
taries, editorials, letters, meeting abstracts and case reports. To
run network meta-analysis, we extracted the number of each
event from studies, papers that did not report those data were
excluded10,14,17,19,23,25,27,33-35.
The screening of titles and abstracts was carried out indepen-
dently by all authors to exclude studies that clearly did not ful-
fill the inclusion criteria. Then, they reviewed the full text of
the remaining papers to identify the final eligibility criteria. Dis-
agreements were resolved through discussions.
Data were extracted from full-text papers by all authors; they
checked precisely extracted data to minimize errors. For each
study, the following data were extracted: the first author’s name,
publication year, outcomes of interest, sample size, type of
treatment, risk of bias assessment and summary results. A con-
trol check between the final extracted data and the original
publications’ data was carried out.
Quality assessment
Quality assessment was carried out independently by two
authors (RBY and SBG). Any discrepancies were resolved by
discussion, and the third reviewer (MA) was consulted if neces-
sary. We applied the AMSTAR-2 appraisal tool to evaluate the
methodological quality of eligible meta-analyses. This tool eval-
uates the quality of systematic reviews with both randomized
and non-randomized studies included36. The characteristics of
the included studies were reported in Table S1. In addition,
Tables 1 and 2 were designed to show results of the AMSTAR-
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2 domain (yes, partial yes and no) of each included study. Fur-
thermore, the secular trend of the number and quality of
included reviews is shown in Figure 1.
Statistical analysis
Statistical analysis was carried out using Stata software (version
13; StataCorp, College Station, TX, USA). For dichotomous out-
comes, the pooled OR comparing each group of treatments
(metformin, glyburide vs insulin), with its 95% confidence inter-
val (CI), was calculated from the numbers of outcome events in
each meta-analysis study. We carried out a network meta-
analysis to merge information across multiple treatments, simul-
taneously, through direct and indirect data to calculate the
pooled OR of maternal and neonatal outcomes in GDM patients
treated with oral antidiabetic agents (metformin or glyburide),
compared with those treated with insulin. Both consistency and
inconsistency (additional variation in the true treatment effect
between designs, where a design is the set of treatments com-
pared in a study) models were run to obtain the results. A ran-
dom effects model was applied to overcome heterogeneity.
Network rank analysis37 was used for ranking of treatments and
reporting the most efficient modality for managing GDM.
Applying the cumulative probabilities, the surface under the
cumulative ranking curves and the mean rank (the mean of the
distribution of the ranking probabilities) were estimated. A net-
work map, network forest and rankogram plots were drawn for
a graphical illustration of data38. In the network map, the size of
the nodes is proportional to the number of studies evaluating
Table 1 | Summary results of methodological quality of meta-analyses using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2)
No. Reference Publication
year
AMSTAR-2 quality items ΨAMSTAR-2
classification
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 Amin M 2015 Y N Y Y Y Y Y Y Y Y Y N Y Y N Y Low
2 Balsells M 2015 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y High
3 Brown J 2017 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y High
4 Brown J 2017 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y High
5 Butalia S 2017 Y N Y Y Y Y Y Y Y Y Y N N N N Y Low
6 Dhulkotia JS 2010 Y N Y Y Y Y Y Y N N Y N N N N N Low
7 Farrar D 2017 Y Y Y Y Y Y Y Y Y Y Y N Y Y PY Y Moderate
8 Farrar D 2016 Y Y Y Y Y Y Y Y Y Y Y PY Y Y PY Y High
9 Feng Y 2017 Y N Y Y Y Y Y Y Y Y Y Y PY Y Y Y Low
10 Gui J 2013 Y N Y Y Y Y Y Y N Y Y N N Y PY Y Low
11 Jiang YF 2015 Y N Y Y Y Y Y Y Y Y Y Y PY Y Y Y Low
12 Kitwitee P 2015 Y Y Y Y Y Y Y Y Y Y Y N Y PY Y Y Moderate
13 Li G 2014 Y N Y Y Y Y Y Y Y N Y PY Y Y Y Y Low
14 Liang HL 2017 Y N Y Y Y Y Y Y Y Y Y N Y Y Y Y Low
15 Moretti ME 2008 Y N Y N N N N N N Y Y N N Y N N Critically low
16 Nicholson W 2009 Y N Y Y Y Y Y Y Y Y Y N N N Y Y Low
17 Poolsup N 2014 Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Low
18 Song R 2017 Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Low
19 Su DF 2017 Y N Y Y Y Y Y Y Y Y Y N N N Y Y Low
20 Zeng YCh 2014 Y N Y Y Y Y Y Y Y Y Y N N N Y Y Low
21 Zhao LP 2015 Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Low
22 Zhu B, 2016 Y N Y Y Y Y Y Y Y Y Y N N N N Y Low
23 L. Tarry-Adkins J 2019 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y High
24 Bao Le-xin 2019 Y Y Y N Y Y Y Y Y N Y N N N Y Y Low
25 Helal, K.F 2020 Y N Y Y Y Y Y Y Y Y Y Y Y Y N Y Low
26 Guo L 2019 Y Y Y Y Y Y Y Y Y Y Y Y Y Y PY Y Moderate
27 Kalafat ER 2018 Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y High
Critical domains include items 2, 4, 7, 9, 11, 13 and 15. ΨAMSTAR-2 classification: High: no or one non-critical weakness; the systematic review pro-
vides an accurate and comprehensive summary of the results of the available studies that address the question of interest. Moderate: more than
one non-critical weakness; the systematic review has more than one weakness, but no critical flaws. It might provide an accurate summary of the
results of the available studies that were included in the review. Low: one critical flaw with or without non-critical weaknesses; the review has a crit-
ical flaw, and might not provide an accurate and comprehensive summary of the available studies that address the question of interest. Critically
low: more than one critical flaw with or without non-critical weaknesses; the review has more than one critical flaw, and should not be relied on
to provide an accurate and comprehensive summary of the available studies. AMSTAR-2, A Measurement Tool to Assess Systematic Reviews; N, no;
PY, partial yes; Y, yes.
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each treatment, and the thickness of the edges is proportional to
the precision of each direct comparison.
Outcome measures
Fetal, maternal and neonatal outcomes of interest were classi-
fied in seven indices composited, including adverse maternal
outcomes, adverse neonatal outcomes, excessive fetal growth
(large for gestational age [LGA] and macrosomia), hypertensive
disorders of pregnancy (pregnancy -induced hypertension
[PIH] and pre-eclampsia), neonatal metabolic disturbance (hy-
perbilirubinemia, and neonatal hypoglycemia), serious neonatal
conditions (neonatal intensive care unit [NICU] admission and
respiratory distress syndrome) and abnormal delivery (cesarean
section, induction of labor). The present study also assessed
separate outcomes, including LGA, macrosomia, hyperbiliru-
binemia, induction of labor, NICU admission, pre-eclampsia,
PIH, preterm birth, neonatal hypoglycemia, small for gesta-
tional age (SGA), maternal hypoglycemia, respiratory distress
syndrome, shoulder dystocia, congenital abnormality, cesarean
section and perinatal mortality.
RESULTS
Search results, study selection, study characteristics and
quality assessment
Figure 2 shows the PRISMA flow diagram of the study. Of 234
studies retrieved through searching databases, 27 studies were
included for methodology quality assessment, and 17 of them
were considered for quantitative synthesis through network
Table 2 | Summary results of methodological quality of the included meta-analyses through A Measurement Tool to Assess Systematic Reviews
(AMSTAR-2) items
Items n (%)
1 Did the research questions and inclusion criteria for the review include the components of PICO
(population, intervention, control group and outcome)?
Yes = 27 (100)
2 Did the report of the review contain an explicit statement that the review methods were established
prior to conduct of the review and did the report justify any significant deviations from the protocol?
Yes = 10 (37)
No = 17 (63)
3 Did the review authors explain their selection of the study designs for inclusion in the review? Yes = 27 (100)
4 Did the review authors use a comprehensive literature search strategy? Yes = 25 (93)
No = 2 (7)
5 Did the review authors perform study selection in duplicate? Yes = 26 (96)
No = 1 (4)
6 Did the review authors perform data extraction in duplicate? Yes = 26 (96)
No = 1 (4)
7 Did the review authors provide a list of excluded studies and justify the exclusions? Yes = 26 (96)
No = 1 (4)
8 Did the review authors describe the included studies in adequate detail? Yes = 26 (96)
No = 1 (4)
9 Did the review authors use a satisfactory technique for assessing the RoB in individual studies that
were included in the review?
Yes = 24 (89)
No = 3 (11)
10 Did the review authors report on the sources of funding for the studies included in the review? Yes = 24 (89)
No = 3 (11)
11 If meta-analysis was justified did the review authors use appropriate methods for statistical
combination of results?
Yes = 27 (100)
12 If meta-analysis was performed did the review authors assess the potential impact of RoB in individual
studies on the results of the meta-analysis or other evidence synthesis?
Yes = 12 (44)
Partial yes=2 (7)
No = 13 (48)
13 Did the review authors account for RoB in individual studies when interpreting/discussing the
results of the review?
Yes = 16 (59)
Partial yes=2 (7)
No = 9 (34)
14 Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity
observed in the results of the review?
Yes = 19 (70)
Partial yes=1 (4)
No = 7 (26)
15 If they performed quantitative synthesis did the review authors carry out an adequate investigation
of publication bias (small study bias) and discuss its likely impact on the results of the review?
Yes = 17 (63)
Partial yes=4 (15)
No = 6 (22)
16 Did the review authors report any potential sources of conflict of interest, including any funding they
received for conducting the review?
Yes = 25 (93)
No = 2 (7)
RoB, risk of bias.
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meta-analysis. Of these, eight studies6,11,18,20,21,26,28,29 assessed
metformin versus insulin, two studies22,24 assessed glyburide
versus insulin, two studies13,39 assessed metformin versus gly-
buride, three studies12,40,41 assessed metformin versus insulin,
glyburide versus insulin and metformin versus glyburide, and
two studies42,43 assessed metformin versus insulin and glyburide
versus insulin. Figure 3 shows map plots of network meta-
analysis of the effects of antidiabetic agents on adverse maternal
and neonatal outcomes in patients with GDM. Also, Figures S1
and S2 show these map plots for other composite and separate
outcomes. Table S1 presents the summary of included meta-
analyses assessing the effects of antidiabetic agents for treatment
of GDM on pregnancy outcomes.
Tables 1 and 2 present the results of the methodological
quality assessment of the studies included. Of a total of 27
included studies for quality assessment, 1 (4%), 17 (63%), 3
(11%) and 6 (22%) obtained critically low, low, moderate and
high quality, respectively (Table 1). Among them, 17 (63%), 2
(7%), 1 (4%), 3 (11%), 0 (0%), 9 (34%) and 6 (22%) did not
fulfill critical domains, including items 2, 4, 7, 9, 11, 13, 15,
respectively, leading to low quality of the study (Table 2). Fig-
ure 1 shows the secular trend of publications based on their
quality; there was no specific trend regarding the studies’ qual-
ity over time.
Results of network meta-analysis
Figure 4 shows the forest plots of the antidiabetic agents’ net-
work for adverse maternal and neonatal outcomes. The results
showed that use of metformin and glyburide was associated
with a lower pooled OR for adverse maternal outcomes com-
pared with insulin (pooled OR 0.74, 95% CI 0.59–0.92 and
pooled OR 0.78, 95% CI 0.66–0.92), respectively. There were
no significant differences in the pooled OR of adverse mater-
nal/neonatal outcomes among patients treated with metformin
compared with those treated with glyburide. Figures S3-S10
show the forest plots for other outcomes of interest. The results
of the estimated probability (%) for being a treatment that is
the most effective remedy in reducing the risk of an adverse
outcome for all studies are presented in Table 3. The results
showed that metformin had the highest probability of being the
best treatment, compared with insulin and glyburide for adverse
neonatal outcomes (90.6%), excessive fetal growth (99.9%),
hypertensive disorders of pregnancy (99.7%), neonatal meta-
bolic disturbance (99.7%), LGA (99.8%), macrosomia (97.9%),
hyperbilirubinemia (75.4%), induction of labor (88.9%), NICU
admission (88%), pre-eclampsia (62.9%), PIH (84.7%), preterm
birth (56.8%) and neonatal hypoglycemia (99.9%), whereas gly-
buride was the best treatment in reducing the risk of adverse



















2009 2010 2013 2014 2015 2016
Publication Year
2017 2018 2019 2020
Figure 1 | Secular trend of publications by their quality.
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(98.2%), abnormal delivery (100%), SGA (45.5%), maternal
hypoglycemia (98.9%), respiratory distress syndrome (88.2%),
shoulder dystocia (48%), congenital abnormality (67.2%) and
caesarean section (79.7%). The results also showed that insulin
had the greatest probability of being the best treatment in
reducing the risk of perinatal mortality (48.4%).
The results of rankograms for antidiabetic agents on the
adverse maternal and neonatal outcomes are also presented in
Figure 5; the results show that the probability of metformin
being the best treatment is much higher than two other modal-
ities for the risk reduction of adverse neonatal outcomes; how-























































Figure 2 | Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram of the study.
Insulin




Figure 3 | Map plots of network meta-analysis of the effects of antidiabetic agents on adverse maternal and neonatal outcomes. The size of the
nodes is proportional to the number of studies evaluating each treatment, and the thickness of the edges is proportional to the precision (the
inverse of the variance) of each direct comparison.
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Figures S11-S13 show the rankograms of other outcomes of
interest. Table S2 provides pooled OR (95% CI) for a combina-
tion of treatments.
Results of subgroup analysis based on the quality assessment
The results of subgroup analysis by excluding low-quality stud-
ies showed that metformin had the highest probability of being
the best treatment in reducing the risk of adverse neonatal out-
comes (91.8%), excessive fetal growth (55.7%), hypertensive dis-
orders of pregnancy (81.3%), neonatal metabolic disturbance
(93.2%), LGA (85.2%), macrosomia (89%) and neonatal hypo-
glycemia (91%), whereas glyburide was the best treatment in
reducing the risk of adverse maternal outcomes (70.5%), serious
neonatal conditions (97.2%), abnormal delivery (97.8%), SGA
(82.8%) and cesarean section (94.3%; Table 4).
DISCUSSION
This is the first study that provided a methodological quality
assessment of published meta-analysis on the effect of antidia-
betic agents for the treatment of GDM. In addition, we provided
a summary result of 17 eligible studies through a network meta-
analysis that identified metformin as the best antidiabetic agent
for the treatment of GDM by reducing the risk of the most
adverse maternal and neonatal outcomes, and findings remained
consistent, even after excluding low-quality studies.
Traditionally, insulin has been considered as a gold standard
for managing hyperglycemic in patients with GDM that have
failed to achieve normal glycemic levels through lifestyle
changes, as it can achieve tight maternal glucose control with-
out the risk of transferring across the placenta21,44. There is also
evidence suggesting that oral antidiabetic agents, mainly met-
formin and glyburide, might be effective and safe alternatives to
insulin for GDM women, especially for those who could not
tolerate the injection, which can be better accepted than insu-
lin4, although these agents have not been approved by the Food
and Drug Administration for this indication yet23, and the use
of oral antidiabetic agents for the treatment of GDM remains
controversial27. It has been shown that a multiple-treatments
meta-analysis (network meta-analysis) is considered as high-
level evidence for developing guidelines, in particular, when
there is an inconsistency among studies. These studies can pro-
vide the most robust and reliable evidence on a specific
topic15,16.
In the present network meta-analysis, we found that met-
formin had the highest probability of being the best treatment,
compared with insulin and glyburide for most outcomes of inter-
est, such as adverse neonatal outcomes, excessive fetal growth,
hypertensive disorders of pregnancy, neonatal metabolic distur-
bance, LGA, macrosomia, hyperbilirubinemia, induction of labor,
NICU admission, preeclampsia, PIH, preterm birth and neonatal
hypoglycemia. To minimize biases due to a low quality of studies,
we excluded these meta-analyses6,13,21,22,24,28,29,41,43,45,46, and ana-
lyzed only moderate-11,40 and high-quality studies12,26,39,42; how-
ever, our preliminary findings remained unchanged after this
Figure 4 | The forest plot of the network meta-analysis of the effects of antidiabetic agents on adverse maternal and neonatal outcomes. Pooled
results within design (from the inconsistency model) are shown as a green square. Overall pooled results are also shown as a red square. The non-
similarity of the “pooled within design” and “pooled overall” results supports the consistency model. A, Glyburide; B, insulin; C, metformin.
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subgroup analysis. Although metformin can cross the placenta,
previous studies showed that it is less likely to cause severe
neonatal hypoglycemia compared with insulin, because met-
formin is not associated with stimulating pancreatic insulin
release or increasing serum insulin levels. Therefore, metformin
can be an effective and safe alternative to insulin for GDM
patients17,46.
Several meta-analyses have compared the effects of antidia-
betic agents on adverse pregnancy outcomes with inconclusive
results6,10-13,17-29,33-35,39-41,43. For example, similarly to the pre-
sent results, a recent meta-analysis of 24 studies suggested that
metformin might have potential benefits for pregnant women
and newborns with no obvious adverse effects17. Likewise,
another meta-analysis of 42 studies showed that metformin had
the highest probability of being the most effective treatment in
reducing the risk of most adverse pregnancy outcomes, com-
pared with insulin or glyburide10. Furthermore, a meta-analysis
of five studies comparing the effects of metformin versus insu-
lin on maternal and neonatal outcomes reported that
metformin is an effective and safe alternative to insulin for
GDM patients. They reported better glycemic control and lower
maternal weight gain with metformin compared with insulin,
making metformin worth using, even when metformin is insuf-
ficient and supplementary insulin is required. Their data also
showed that metformin significantly reduced the gestational
hypertension disorders in GDM patients, probably through
modifying the endothelial activation and maternal inflammatory
response of insulin resistance20. Another meta-analysis of five
studies showed that metformin is comparable with insulin in
glycemic control and neonatal outcomes, and suggested it as
more suitable for women with mild GDM6. Furthermore, one
meta-analysis of 41 studies showed that metformin could be a
safe and effective treatment for GDM40. Another meta-analysis
of five studies showed that metformin is comparable with insu-
lin in glycemic control and neonatal outcomes, and suggested it
as more suitable for women with mild GDM6. Moreover, one
meta-analysis of 41 studies showed that metformin could be a
safe and effective treatment for GDM40. Another meta-analysis
of 15 studies showed that metformin use can be associated with
a reduced incidence of hypertensive disorders during preg-
nancy35. Meta-analysis carried out by Kitwitee et al.11 showed
that although GDM patients treated with both metformin and
insulin have comparable glycemic control profile, metformin
use was associated with a lower risk of neonatal hypoglycemia.
Also, Li et al.21, during a meta-analysis of 11 studies, found
that metformin can significantly reduce most adverse maternal
and neonatal outcomes. Meta-analysis carried out by Poolsup
et al.43 suggested that because of the favorable effects of met-
formin in treating GDM, this remedy can be considered as an
efficacious alternative to insulin, especially for patients with a
mild form of disease. Zhao et al.28 suggested that although
there is no clinically relevant difference in the efficacy or safety
between metformin and insulin, metformin might be a good
choice for GDM because of the lower risk of PIH. Balsells
et al.12, during a meta-analysis of 15 studies on patients with
GDM, showed that although metformin (plus insulin when
required) seems to be slightly better than insulin, glyburide is
clearly inferior to both insulin and metformin. Although most
meta-analyses showed higher efficacy of metformin in compar-
ison with insulin therapy, a limited number of meta-analyses
showed superiority of glyburide19, or similar efficacy of insulin
and oral antidiabetic agents14,23,42.
The present network meta-analysis also showed that gly-
buride was the best treatment in reducing the risk of some
adverse maternal outcomes, such as maternal hypoglycemia,
abnormal delivery, shoulder dystocia and caesarean section, and
neonatal outcomes, such as serious neonatal conditions, SGA,
respiratory distress syndrome and congenital abnormality, find-
ings that remained significant even after excluding low-quality
studies. Similar to the present results, a meta-analysis of 24
studies showed that glyburide is an effective drug compared
with insulin in the management of some adverse pregnancy
outcomes, such as cesarean section, findings that might suggest
Table 3 | Estimated probability (%) of a treatment being the most
effective in reducing the risk of a dichotomous outcome for all studies
Outcomes Treatments
Metformin Glyburide Insulin
Adverse maternal outcomes† 29.5 70.5 0.0
Adverse neonatal outcomes‡ 90.6 9.3 0.1
Excessive fetal growth 99.9 0.1 0.0
Hypertensive disorders of pregnancy 99.7 0.2 0.1
Neonatal metabolic disturbance 99.7 0.2 0.1
Serious neonatal conditions 1.8 98.2 0.0
Abnormal delivery 0.0 100.0 0.0
LGA 99.8 0.2 0.0
Macrosomia 97.9 1.8 0.4
Hyperbilirubinaemia 75.4 22.3 2.3
Induction of labor 88.9 8.4 2.8
NICU admission 88.0 12.0 0.0
Pre-eclampsia 62.9 32.5 4.6
PIH 84.7 15.3 0.0
Preterm birth 56.8 33.2 10.0
Neonatal hypoglycemia 99.9 0.1 0.0
SGA 43.6 45.5 10.9
Maternal hypoglycemia 1.1 98.9 0.0
Respiratory distress syndrome 7.1 88.2 4.7
Shoulder dystocia 38.9 48.0 13.1
Congenital abnormality 28.7 67.2 4.2
Cesarean section 18.3 79.7 2.0
Perinatal mortality 38.9 12.6 48.4
†Adverse maternal outcomes including: induction of labor, pre-
eclampsia, pregnancy-induced hypertension (PIH), maternal hypo-
glycemia and cesarean section. ‡Adverse neonatal outcomes including:
large for gestational age (LGA), macrosomia, hyperbilirubinemia, neona-
tal intensive care unit (NICU) admission, preterm birth, small for gesta-
tional age (SGA), neonatal hypoglycemia, respiratory distress syndrome,
shoulder dystocia and congenital abnormality.
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the potential clinical benefits of glyburide, compared with met-
formin or insulin19. Also, a network meta-analysis of 32 ran-
domized controlled trials (RCTs) carried out by Liang et al.34
showed that the incidence of admission to NICU was higher
with insulin therapy compared with glyburide, whereas this
drug has the highest incidence of macrosomia, pre-eclampsia,
hyperbilirubinemia, neonatal hypoglycemia, shortest gestational
age at delivery and lowest mean birthweight. In contrast, Jiang
et al.41, during a meta-analysis of 18 studies, showed that gly-
buride treatment is associated with an increased risk of neona-
tal hypoglycemia, high maternal weight gain, high neonatal
birthweight and macrosomia. Also, a meta-analysis carried out
by Zeng et al.27 showed that although glyburide is as effective
as insulin, the risk of neonatal hypoglycemia, high fetal birth-
weight and macrosomia were higher with its use. However,
insufficient data were available to compare the efficacy of gly-
buride with metformin and insulin; it seems that the effective-
ness and safety of glyburide require future evaluation by well-
designed RCTs with appropriate sample sizes.
Despite there being several meta-analyses of trials investigating
the effects of oral antidiabetic agents and insulin therapy on
adverse maternal and neonatal outcomes in patients with GDM,
their results are often conflicting, and there is insufficient high-
quality evidence to be able to draw any meaningful conclusions
as to the benefits of oral antidiabetic pharmacological agents over
insulin therapy due to including non-randomized studies, small
sample size of trials, limited reporting of data for the adverse out-
comes, diversities in thresholds for diagnosis of GDM and or the
definition of outcomes, and the lack of sufficient data on the
long-term offspring outcomes in patients with GDM treated with
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Figure 5 | Rankograms of the network meta-analysis of the effects of antidiabetic agents on adverse maternal and neonatal outcomes, showing
the probability for every treatment being in a particular order with predictive probabilities in neonatal and maternal adverse events.
Table 4 | Estimated probability (%) of a treatment being the most




LGA 85.2 14.8 0.0
Adverse maternal outcomes 29.5 70.5 0.0
Adverse neonatal outcomes 91.8 8.1 0.0
Excessive fetal growth 55.7 44.3 0.0
Hypertensive disorders of pregnancy 81.3 17.4 1.3
Neonatal metabolic disturbance 93.2 6.8 0.0
Serious neonatal conditions 2.5 97.2 0.3
Abnormal delivery 0.3 97.8 1.9
Macrosomia 89.0 11.0 0.0
Neonatal hypoglycemia 91.0 0.9 0.0
SGA 7.3 82.8 9.9
Cesarean section 4.3 94.3 1.4
LGA, large for gestational age; SGA, small for gestational age.
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that in most RCTs, a significant proportion of patients who failed
to achieve adequate control with oral antidiabetic agents might
then switch to insulin; it is difficult to determine whether
enhanced response is solely attributable to oral antidiabetic agents
(metformin or glyburide) or if insulin also contributed to the
improvement27,43. Future well-designed randomized placebo-
controlled double-blind multicenter trials with an approach of
intention-to-treat are still required for a more accurate conclu-
sion, and to provide additional evidence for the safety and effi-
cacy of antidiabetic agents in the treatment of GDM.
The greatest strength of the present study was its design, as
the first network meta-analysis consisted of all meta-analyses
comparing the effects of oral antidiabetic agents and insulin
therapy, assessing the methodological quality of the studies
using a specific tool for assessing multiple systematic reviews,
and a then carrying out a subgroup analysis based on the stud-
ies’ quality. Although we aimed to minimize all possible biases
in this meta-analysis, it should be noted that there was signifi-
cant heterogeneity among studies. These heterogeneities were
partly predictable and might have resulted from clinical hetero-
geneity related to variability in diagnostic thresholds for GDM,
age, BMI, methods of outcomes assessment, race and ethnicity;
however, using a random effects model somehow adjusted these
issues by assigning lower weights to studies with higher uncer-
tainty. In addition, sparse data in some outcomes, such as
shoulder dystopia, prenatal mortality and SGA, caused higher
uncertainty appearing in wide 95% CIs and misleading infer-
ences. It should also be considered that in many RCTs, patients
might require insulin therapy after treatment with metformin
due to failure to achieve adequate control with oral antidiabetic
agents. However, most RCTs did not mention the details of the
methods and whether they used an intention-to-treat approach
for their data analysis. Also, pooling meta-analyses can result in
the duplication of studies, which might affect studies’ assigned
weight on the pooling process and leads to misestimating the
overall measure of interest. All these limitations should be con-
sidered when interpreting the findings. Data and software codes
are available on request.
In conclusion, although most of the available meta-analyses
were of low quality, the results of the available literature
showed that metformin can be considered as the best alterna-
tive to insulin therapy for women with GDM because of mater-
nal and perinatal outcomes comparable with insulin. The
results need to be further updated by including future more
qualified studies.
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Figure S1 | Map plots of the anti-gestational diabetes mellitus network for maternal and neonatal adverse events. The size of the
nodes is proportional to the number of studies evaluating each treatment, and the thickness of the edges is proportional to the pre-
cision (the inverse of the variance) of each direct comparison.
Figure S2 | Map plots of the anti-gestational diabetes mellitus network for maternal and neonatal hypoglycemia. The size of the
nodes is proportional to the number of studies evaluating each treatment, and the thickness of the edges is proportional to the pre-
cision (the inverse of the variance) of each direct comparison.
Figures S3-S10 | The forest plot for the anti-gestational diabetes mellitus network for adverse events. The individual study results,
grouped by treatment contrast and design. Pooled results within the design (from the inconsistency model) are shown as a green
square. Overall pooled results are also shown as a red square. The non-similarity of the “pooled within design” and “pooled over-
all” results supports the consistency model.
Figures S11-S13 | Rankograms for the anti-gestational diabetes mellitus network showing the probability for every treatment being
in a particular order with predictive probabilities in different adverse events.
Table S1 | Characteristics of included meta-analyses studies in methodological quality assessment
Table S2 | Pooled odds ratios (95% confidence intervals) obtained from meta-analyses for pregnancy outcomes by different treat-
ment design.
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